Scott J Cameron1,2, Doran S Mix3, Sara K Ture4, Rachel A Schmidt4, Amy Mohan4, Daphne Pariser4, Michael C Stoner3, Punit Shah5, Lijun Chen5, Hui Zhang5, David J Field4, Kristina L Modjeski4, Sandra Toth3, Craig N Morrell4,2. 1. From the Aab Cardiovascular Research Institute (S.J.C., S.K.T., R.A.S., A.M., D.P., D.J.F., K.L.M., C.N.M.) Scott_Cameron@urmc.rochester.edu. 2. Division of Cardiology, Department of Medicine (S.J.C., C.N.M.). 3. Division of Vascular Surgery, Department of Surgery (D.S.M., M.C.S., S.T.), University of Rochester School of Medicine, NY. 4. From the Aab Cardiovascular Research Institute (S.J.C., S.K.T., R.A.S., A.M., D.P., D.J.F., K.L.M., C.N.M.). 5. Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD (P.S., L.C., H.Z.).
Abstract
OBJECTIVE: Reduced blood flow and tissue oxygen tension conditions result from thrombotic and vascular diseases such as myocardial infarction, stroke, and peripheral vascular disease. It is largely assumed that while platelet activation is increased by an acute vascular event, chronic vascular inflammation, and ischemia, the platelet activation pathways and responses are not themselves changed by the disease process. We, therefore, sought to determine whether the platelet phenotype is altered by hypoxic and ischemic conditions. APPROACH AND RESULTS: In a cohort of patients with metabolic and peripheral artery disease, platelet activity was enhanced, and inhibition with oral antiplatelet agents was impaired compared with platelets from control subjects, suggesting a difference in platelet phenotype caused by the disease. Isolated murine and human platelets exposed to reduced oxygen (hypoxia chamber, 5% O2) had increased expression of some proteins that augment platelet activation compared with platelets in normoxic conditions (21% O2). Using a murine model of critical limb ischemia, platelet activity was increased even 2 weeks postsurgery compared with sham surgery mice. This effect was partly inhibited in platelet-specific ERK5 (extracellular regulated protein kinase 5) knockout mice. CONCLUSIONS: These findings suggest that ischemic disease changes the platelet phenotype and alters platelet agonist responses because of changes in the expression of signal transduction pathway proteins. Platelet phenotype and function should, therefore, be better characterized in ischemic and hypoxic diseases to understand the benefits and limitations of antiplatelet therapy.
OBJECTIVE: Reduced blood flow and tissue oxygen tension conditions result from thrombotic and vascular diseases such as myocardial infarction, stroke, and peripheral vascular disease. It is largely assumed that while platelet activation is increased by an acute vascular event, chronic vascular inflammation, and ischemia, the platelet activation pathways and responses are not themselves changed by the disease process. We, therefore, sought to determine whether the platelet phenotype is altered by hypoxic and ischemic conditions. APPROACH AND RESULTS: In a cohort of patients with metabolic and peripheral artery disease, platelet activity was enhanced, and inhibition with oral antiplatelet agents was impaired compared with platelets from control subjects, suggesting a difference in platelet phenotype caused by the disease. Isolated murine and human platelets exposed to reduced oxygen (hypoxia chamber, 5% O2) had increased expression of some proteins that augment platelet activation compared with platelets in normoxic conditions (21% O2). Using a murine model of critical limb ischemia, platelet activity was increased even 2 weeks postsurgery compared with sham surgery mice. This effect was partly inhibited in platelet-specific ERK5 (extracellular regulated protein kinase 5) knockout mice. CONCLUSIONS: These findings suggest that ischemic disease changes the platelet phenotype and alters platelet agonist responses because of changes in the expression of signal transduction pathway proteins. Platelet phenotype and function should, therefore, be better characterized in ischemic and hypoxic diseases to understand the benefits and limitations of antiplatelet therapy.
Authors: Scott J Cameron; Sara K Ture; Deanne Mickelsen; Enakshi Chakrabarti; Kristina L Modjeski; Scott McNitt; Michael Seaberry; David J Field; Nhat-Tu Le; Jun-Ichi Abe; Craig N Morrell Journal: Circulation Date: 2015-05-01 Impact factor: 29.690
Authors: Johanna P van Geffen; Marie-Claire Kleinegris; Remco Verdoold; Constance C F M J Baaten; Judith M E M Cosemans; Kenneth J Clemetson; Hugo Ten Cate; Mark Roest; Bas de Laat; Johan W M Heemskerk Journal: Thromb Res Date: 2015-01-06 Impact factor: 3.944
Authors: Jennifer O Nwankwo; Thomas Gremmel; Anja J Gerrits; Farha J Mithila; Rod R Warburton; Nicholas S Hill; Yunzhe Lu; Lauren J Richey; Joseph A Jakubowski; Andrew L Frelinger; Athar H Chishti Journal: Thromb Res Date: 2017-10-26 Impact factor: 3.944
Authors: Paul Cherian; Graeme J Hankey; John W Eikelboom; Jim Thom; Ross I Baker; Andrew McQuillan; Janelle Staton; Qilong Yi Journal: Stroke Date: 2003-08-07 Impact factor: 7.914
Authors: Ina Nemet; Prasenjit Prasad Saha; Nilaksh Gupta; Weifei Zhu; Kymberleigh A Romano; Sarah M Skye; Tomas Cajka; Maradumane L Mohan; Lin Li; Yuping Wu; Masanori Funabashi; Amanda E Ramer-Tait; Sathyamangla Venkata Naga Prasad; Oliver Fiehn; Federico E Rey; W H Wilson Tang; Michael A Fischbach; Joseph A DiDonato; Stanley L Hazen Journal: Cell Date: 2020-03-05 Impact factor: 41.582
Authors: Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty Journal: Arterioscler Thromb Vasc Biol Date: 2019-12-23 Impact factor: 8.311
Authors: Mina K Chung; David A Zidar; Michael R Bristow; Scott J Cameron; Timothy Chan; Clifford V Harding; Deborah H Kwon; Tamanna Singh; John C Tilton; Emily J Tsai; Nathan R Tucker; John Barnard; Joseph Loscalzo Journal: Circ Res Date: 2021-04-15 Impact factor: 17.367
Authors: Rens L J Van Meijel; Ping Wang; Freek Bouwman; Ellen E Blaak; Edwin C M Mariman; Gijs H Goossens Journal: Front Physiol Date: 2022-01-04 Impact factor: 4.566
Authors: Beom Soo Kim; David S Auerbach; Hamza Sadhra; Matthew Godwin; Rohan Bhandari; Frederick S Ling; Amy Mohan; David I Yule; Larry Wagner; David Q Rich; Sara Ture; Craig N Morrell; Livia Timpanaro-Perrotta; Arwa Younis; Ilan Goldenberg; Scott J Cameron Journal: Arterioscler Thromb Vasc Biol Date: 2020-11-12 Impact factor: 8.311